WO2015048438A1 - Immunogènes du vih-1 - Google Patents

Immunogènes du vih-1 Download PDF

Info

Publication number
WO2015048438A1
WO2015048438A1 PCT/US2014/057708 US2014057708W WO2015048438A1 WO 2015048438 A1 WO2015048438 A1 WO 2015048438A1 US 2014057708 W US2014057708 W US 2014057708W WO 2015048438 A1 WO2015048438 A1 WO 2015048438A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
composition
vector
immunogens
science
Prior art date
Application number
PCT/US2014/057708
Other languages
English (en)
Inventor
Barton F. Haynes
Feng Gao
Beatrice H. Hahn
George M. Shaw
Hua-Xin Liao
Original Assignee
Duke University
The Trustees Of The Univesity Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, The Trustees Of The Univesity Of Pennsylvania filed Critical Duke University
Publication of WO2015048438A1 publication Critical patent/WO2015048438A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La présente invention concerne en général le VIH-1, et en particulier des immunogènes du VIH-1. Elle concerne des méthodes d'utilisation de tels immunogènes pour induire la production d'anticorps pouvant largement neutraliser le VIH-1 chez un sujet (par exemple, un humain)
PCT/US2014/057708 2013-09-28 2014-09-26 Immunogènes du vih-1 WO2015048438A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361884014P 2013-09-28 2013-09-28
US61/884,014 2013-09-28

Publications (1)

Publication Number Publication Date
WO2015048438A1 true WO2015048438A1 (fr) 2015-04-02

Family

ID=52744502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/057708 WO2015048438A1 (fr) 2013-09-28 2014-09-26 Immunogènes du vih-1

Country Status (1)

Country Link
WO (1) WO2015048438A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040562A2 (fr) * 2010-09-24 2012-03-29 International Aids Vaccine Initiative Nouveaux anticorps à pouvoir de neutralisation du vih-1 étendu
WO2013006688A2 (fr) * 2011-07-05 2013-01-10 Duke University Immunogènes gp120 à extrémité n-terminale délétée

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040562A2 (fr) * 2010-09-24 2012-03-29 International Aids Vaccine Initiative Nouveaux anticorps à pouvoir de neutralisation du vih-1 étendu
WO2013006688A2 (fr) * 2011-07-05 2013-01-10 Duke University Immunogènes gp120 à extrémité n-terminale délétée

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRAY ET AL.: "The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD 4+ T cell decline and high viral load during acute infection", JOURNAL OF VIROLOGY, vol. 85, no. 10, 2011, pages 4828 - 4840 *
HUSSAIN ET AL.: "Broadly neutralizing antibody responses in a subset of HIV-1-infected individuals in Chennai, India : potential avenues for vaccine design", JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE (JIAPAC)., February 2013 (2013-02-01), pages 1 - 8 *
WALKER ET AL.: "Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target", SCIENCE, vol. 326, no. 5950, 2009, pages 285 - 289 *

Similar Documents

Publication Publication Date Title
Doria-Rose et al. Strategies to guide the antibody affinity maturation process
Haynes et al. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Dennison et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
Yan et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine
US10561725B2 (en) Method of inducing the production of protective anti-HIV-1 antibodies
Liu et al. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
KR20230025670A (ko) Sars-cov-2 백신
US10322141B2 (en) Compositions comprising CH848 envelopes and uses thereof
US11814413B2 (en) Compositions comprising modified HIV envelopes
Dunham et al. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and-18
Yi et al. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses
US20210052720A1 (en) Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions
WO2015048610A1 (fr) Immunogènes de vih-1 et anticorps contre vih-1 largement neutralisants
US20220380412A1 (en) Compositions comprising v2 opt hiv envelopes
WO2015048438A1 (fr) Immunogènes du vih-1
Zhang et al. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade
WO2015048517A1 (fr) Mutants d'échappement
RU2626605C2 (ru) Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
Munis Envelope glycoproteins of vesiculoviruses: characteristics of antibody interactions and immunogenicity
Mosa Candidate Bivalent HCV Vaccine: A Novel Approach to Vaccine Design for Hyper-Variable Viruses
WO2023064424A2 (fr) Compositions comprenant des enveloppes de vih opt v2
WO2019069273A1 (fr) Mva recombiné à env de vih-1 modifiée
CA2983259A1 (fr) Immunisation en essaim au moyen d'enveloppes de ch505
Montero Antigenicity and immunogenicity of the membrane proximal external region of the HIV-1 envelope protein gp41

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14849456

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14849456

Country of ref document: EP

Kind code of ref document: A1